NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

The financing was raised by a new investor that Bennani declined to identify, and will be used to accelerate clinical trials for its technology. Since its inception, it has raised $15 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.